Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

Core Insights - Stereotaxis has received FDA approval for its MAGiC™ Magnetic Interventional Ablation Catheter, marking a significant milestone in robotic cardiac ablation technology [1][2]. Company Overview - Stereotaxis is a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, focusing on the development of robotic systems and solutions for interventional laboratories [5]. - The company's technology has been utilized to treat over 150,000 patients globally, enhancing patient care through robotic precision and safety [5]. Product Details - The MAGiC catheter is designed for cardiac ablation procedures to treat heart arrhythmias, particularly in complex and underserved patient populations [2][4]. - It utilizes computer-controlled magnetic fields for navigation, providing enhanced maneuverability, precision, and stability compared to traditional catheters [2]. - The catheter is indicated for various electrophysiological mapping and ablation procedures, especially in patients with congenital heart disease where conventional access is limited [4]. Industry Impact - The approval of the MAGiC catheter is expected to advance the field of robotic magnetic navigation in electrophysiology, positively impacting the care of patients with complex arrhythmias [3]. - The innovation is anticipated to support efforts in providing safe and effective therapies to underserved patient populations [4].